The Burden of Rare Tumors in China: Results of a Population-Study

Rongshou Zheng,Shuhang Wang,Peiwen Ma,Yuan Fang,Shaoming Wang,Siwei Zhang,Yue Yu,Ning Jiang,Huiyao Huang,Huilei Miao,Hongmei Zeng,Ru Chen,Kexin Sun,Ning Li,Wenqiang Wei,Jie He

DOI: https://doi.org/10.2139/ssrn.4013910

2022-01-01

SSRN Electronic Journal

Abstract:There are few studies on the burden of rare tumors in Chinese population. We analyze the patterns of incidence and survival of rare tumors in Chinese population with the data abstracted from the database of National Central Cancer Registry of China (NCCR). Cancer types were classified based on the criteria developed by Surveillance of Rare Cancer in Europe (RARECARE). The crude incidence rate and age-standardized incidence rate (ASIR) and survival rates for each rare cancer type were estimated for diagnoses from 2013 to 2016. The definition of rare tumors was based on the crude cancers incidence rate with a cutoff of less than 2.5 per 100,000 populations per year in China. We gave a systematic statistic on the rare cancer incidence and survival rates. About 23.4% of new cancer patients in China are diagnosed as rare tumors. The 5-year relative survival for rare cancer patients are 46.8% in male and 60.5% in female. This study indicates that continuous efforts is necessary to develop interventions including cancer prevention, screening, and effective treatment to reduce the burden of rare cancers in China.There are few studies on the burden of rare tumors in Chinese population. We analyze the patterns of incidence and survival of rare tumors in Chinese population with the data abstracted from the database of National Central Cancer Registry of China (NCCR). Cancer types were classified based on the criteria developed by Surveillance of Rare Cancer in Europe (RARECARE). The crude incidence rate and age-standardized incidence rate (ASIR) and survival rates for each rare cancer type were estimated for diagnoses from 2013 to 2016. The definition of rare tumors was based on the crude cancers incidence rate with a cutoff of less than 2.5 per 100,000 populations per year in China. We gave a systematic statistic on the rare cancer incidence and survival rates. About 23.4% of new cancer patients in China are diagnosed as rare tumors. The 5-year relative survival for rare cancer patients are 46.8% in male and 60.5% in female. This study indicates that continuous efforts is necessary to develop interventions including cancer prevention, screening, and effective treatment to reduce the burden of rare cancers in China.